Sign In
Buy CDNA
$38.37
-1.36 (-3.42%)
At Close: Jul 20, 2026
CareDx Adds to AlloSure Kidney and HeartCare Utility and Clinical Data at 2024 American Society of Transplant Surgeons Winter Symposium
04:05pm, Thursday, 11'th Jan 2024
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healt
How Much Upside is Left in CareDx (CDNA)? Wall Street Analysts Think 26.72%
11:16am, Friday, 08'th Dec 2023
The average of price targets set by Wall Street analysts indicates a potential upside of 26.7% in CareDx (CDNA). While the effectiveness of this highly sought-after metric is questionable, the positiv
Can CareDx (CDNA) Climb 29.79% to Reach the Level Wall Street Analysts Expect?
11:17am, Wednesday, 22'nd Nov 2023
The mean of analysts' price targets for CareDx (CDNA) points to a 29.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts
CareDx, Inc (CDNA) Q3 2023 Earnings Call Transcript
08:13pm, Wednesday, 08'th Nov 2023
CareDx, Inc (NASDAQ:CDNA ) Q3 2023 Results Conference Call November 8, 2023 4:30 PM ET Company Participants Greg Chodaczek - Gilmartin Group, Managing Director Alex Johnson - President of Patient and
CareDx (CDNA) Surges 16.6%: Is This an Indication of Further Gains?
09:01am, Monday, 06'th Nov 2023
CareDx (CDNA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in t
Compared to Estimates, CareDx (CDNA) Q2 Earnings: A Look at Key Metrics
10:42am, Wednesday, 09'th Aug 2023
Although the revenue and EPS for CareDx (CDNA) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street es
CareDx (CDNA) Reports Q2 Loss, Tops Revenue Estimates
07:42pm, Tuesday, 08'th Aug 2023
CareDx (CDNA) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.42. This compares to loss of $0.13 per share a year ago.
CareDx (CDNA) Soars 20.6%: Is Further Upside Left in the Stock?
10:15am, Monday, 10'th Jul 2023
CareDx (CDNA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road
Why Shares of CareDx Are Jumping Friday
12:26pm, Friday, 07'th Jul 2023
CareDx specializes in diagnostic testing for transplant patients. The company's revenue declined 3% year over year in the first quarter.
CareDx to Participate in Upcoming Investor Conferences
07:00am, Thursday, 01'st Jun 2023
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-val
CareDx to Report First Quarter 2023 Financial Results
07:01am, Monday, 08'th May 2023
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healt
CareDx, Inc. (CDNA) Q4 2022 Results Earnings Call Transcript
10:37pm, Monday, 27'th Feb 2023
CareDx, Inc. (NASDAQ:CDNA ) Q4 2022 Earnings Conference Call February 27, 2023 4:30 PM ET Company Participants Greg Chodaczek - IR Reginald Seeto - CEO Abhishek Jain - Interim CFO Conference Call Part
CareDx (CDNA) Reports Q4 Loss, Tops Revenue Estimates
06:49pm, Monday, 27'th Feb 2023
CareDx (CDNA) delivered earnings and revenue surprises of -16.67% and 0.38%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
08:30am, Friday, 27'th Jan 2023
The growth-focused money manager is making moves.
CareDx: What To Make Of The New Share Repurchase Program (Rating Upgrade)
06:54am, Monday, 12'th Dec 2022
CDNA's share repurchase program will reduce outstanding shares by 8% based on current prices. This and management's short-term profitability ambitions warrant a rating upgrade. The company has a stron
